期刊
EPMA JOURNAL
卷 7, 期 -, 页码 -出版社
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1186/s13167-016-0074-2
关键词
Rare diseases; Biomarker panels; Multi-omics; Predictive preventive personalized medicine; Innovation; Prognosis; Screening; Individualized therapy; Biobank; Drug targets
资金
- TUBITAK, Turkey [BIDEB-2232, 213S006]
- Hacettepe Research Fund [THD-2015-7301]
There are more than 8000 rare diseases (RDs) that affect >5 % of the world's population. Many of the RDs have no effective treatment and lack of knowledge creates delayed diagnosis making management difficult. The emerging concept of the personalized medicine allows for early screening, diagnosis, and individualized treatment of human diseases. In this context, the discovery of biomarkers in RDs will be of prime importance to enable timely prevention and effective treatment. Since 80 % of RDs are of genetic origin, identification of new genes and causative mutations become valuable biomarkers. Furthermore, dynamic markers such as expressed genes, metabolites, and proteins are also very important to follow prognosis and response the therapy. Recent advances in omics technologies and their use in combination can define pathophysiological pathways that can be drug targets. Biomarker discovery and their use in diagnosis in RDs is a major pillar in RD research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据